Asthma is a common lung condition affecting nearly 340 million people in developed countries & nearly 600 million in India & China. The disease is mainly caused due to allergens & pollutants (A/P). It is characterized by chronic airway inflammation & swelling leading to narrowing of the airways and respiratory distress. The main respiratory symptoms include wheezing sound, shortness of breath, chest tightness & cough.

Recently, scientific advances clearly proved chronic A/P exposure leads to the (1) Formation of intercellular gaps in the nasal mucosa (2) Stimulation of TRP – Transient Ankyrin Potential – receptor channels (3) Release of TSLP – Thymus stromal LymphoProtein) (4) Triggering of neurogenic inflammation (5) Release of inflammatory cytokines, IgE, Histamine, leukotrienes, (6) Bronchial smooth muscle contraction & (7) Respiratory distress.

Ideal Treatment Approach:

An ideal “preventive” treatment should stop A/P contact with the nasal surface and repair damages nasal epithelium to stop systemic entry of A/Ps which should minimize allergenic & inflammatory cascades. The treatment should remove all the contaminants, including allergens, pollutants, proteins, & heavy metal particles from the nasal surface. Keeping the nasal surface protected, clean, hydrated, & intact should automatically supress the need for chemical treatments.


Asmidine is a new generation of preventive treatment against respiratory distress (ex. asthma) affecting over 1 billion people in the world

Currently available treatments:

There is no drug to prevent A/P contact with nasal surface or to remove “all” the undesired contaminants in contact with the nasal mucosa. The intercellular passage continues allowing A/P entry & subsequent allergen / inflammatory cascade. Anti-inflammatory drugs & corticosteroids, Beta-2 agonists, leukotriene antagonists, mast cell stabilizers, antihistamines, monoclonal anti-IgE therapy, & methylxanthine as bronchodilators, are help ease individual symptom but they all are mono-target & provide only symptomatic relief.

VITROBIO’s Completely NEW Therapeutic Approach:

After 20 years of R&D, Vitrobio developed & patented an osmotically active, non-irritant, flexible & long-lasting liquid bandage which can act as an A/P protective film over the nasal surface in a polluted environment. Being osmotic & absorbent, the film attracts & traps all the contaminants present on the nasal surface thereby cleaning the nasal mucosa & preparing a favourable ground for cell growth & repair. A clean, hydrated, chemical & protein free epithelial layer can fill-up the intercellular gaps within 12-24h. An intact nasal barrier does not allow A/P entry into the body & subsequently stops continuous allergen / inflammatory cascade. ASMIDINE is the 1st multi-target, preventive treatment against all types of respiratory distresses.

Product Presentation: 15 ml spray for topical application on the nasal mucosa.

Posology: PREVENTIVE & SYMPTOMATIC TREATMENTS: 3-4 sprays of PIRDAL in each nostril, preferably half an hour before being exposed to the polluted asthma-triggering environment.

Regulatory Status: Due to the mechanical & topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structures, this product is classified as Class I (soon Class II) Medical Device in EU. 

Contraindications: None (can be used over 6 years of age). 

Side Effects: None

Clinical Efficacy:

A GINA recommended full clinical trial on 180 patients v/s commonly used drugs is in progress (2020)

ASMIDINE is a new generation of preventive treatment against respiratory distress (ex. asthma) affecting over 1 billion people in the world.

The product is totally safe, can be used by children, can be administered with other commonly used drugs without any interactions, is based on a scientific & logical multi-target approach & is ready to market.

For full scientific details: Contact VITROBIO, France.